— Webcast and Conference Call to Follow —
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 25, 2016--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing desensitization treatments for food allergies, today
announced that its financial results for the fourth quarter and full
year 2015 will be released on Thursday, March 3, 2016, after the markets
close. At 5:00 p.m. Eastern Time, Aimmune management will host a
conference call to discuss its financial results and provide a general
The conference call will be accessible via the company’s website at www.aimmune.com
on the Events page under Investor Relations. Please connect to the
company’s website at least 15 minutes prior to the start of the
conference call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
1-877-497-1438 (U.S.) or 1-262-558-6296 (international) and provide the
conference call passcode 60127471 to join by phone.
A telephone replay will be available approximately two hours after the
call’s completion until 11:59 p.m. Eastern Time on March 7, 2016. Access
numbers for the telephone replay are 1-855-859-2056 or 1-404-537-3406;
the passcode is 60127471. A webcast replay will also be archived on www.aimmune.com
for 30 days.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for peanut allergy and other
life-threatening food allergies. The company’s characterized oral
desensitization immunotherapy (CODIT™) system, an approach to oral
immunotherapy (OIT), uses rigorously characterized product candidates
with gradual, controlled up-dosing protocols to obtain clinically
meaningful desensitization to food allergens. Aimmune Therapeutics
initiated the Phase 3 PALISADE trial of its lead product, AR101, a
complex mixture of natural peanut proteins and pharmaceutical-grade
ingredients for the treatment of peanut allergy, one of the most common
food allergies, in early 2016. AR101 has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160225005707/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,